Fitch Kathryn, Pelizzari Pamela M, Pyenson Bruce
Principal and Healthcare Consultant, Milliman, Inc, New York, NY.
Healthcare Consultant, Milliman, Inc, New York, NY.
Am Health Drug Benefits. 2016 Apr;9(2):96-104.
Although the medical and economic burden of heart failure in the United States is already substantial, it will likely grow as the population ages and life expectancy increases. Not surprisingly, most of the heart failure burden is borne by individuals aged ≥65 years, many of whom are in the Medicare population. The population-based utilization and costs of inpatient care for Medicare beneficiaries with heart failure are not well understood by payers and providers.
To create a real-world view of utilization and costs associated with inpatient admissions, readmissions, and admissions to skilled nursing facilities among Medicare fee-for-service (FFS) beneficiaries with heart failure.
The study used the 2011 and 2012 Medicare 5% sample limited data set to perform a retrospective analysis of claims data. The look-back year that was used to identify certain patient characteristics was 2011, and 2012 was the analysis period for the study. Beneficiaries with heart failure were defined as those who had ≥1 acute inpatient, emergency department, nonacute inpatient, or outpatient claims in 2012 containing an International Classification of Diseases, Ninth Revision code for heart failure. To be included in the study, beneficiaries with heart failure had to have eligibility for ≥1 months in 2012 and in all 2011 months, with Part A and Part B eligibility in all the study months, and no enrollment in an HMO (Medicare Advantage plan). Utilization of inpatient admissions, inpatient readmissions, and skilled nursing facility admissions in 2012 were reported for Medicare FFS beneficiaries with heart failure and for all Medicare FFS beneficiaries. The costs for key metrics included all allowed Medicare payments in 2012 US dollars.
The 2012 Medicare FFS population for this study consisted of 1,461,935 patients (1,301,545 without heart failure; 160,390 with heart failure); the heart failure prevalence was 11%. The Medicare-allowed cost per member per month (PMPM) was $3395 for a patient with heart failure, whereas the allowed cost for the total Medicare population was $1045 PMPM. The Medicare-allowed amounts for the population with heart failure accounted for 34% of the total annual Medicare FFS population-allowed amounts. The heart failure population constituted 41.5%, 55.3%, and 49.5% of total Medicare FFS inpatient admissions, readmissions, and admissions to skilled nursing facilities, respectively. The costs of inpatient admissions, readmissions, and admissions to skilled nursing facilities among the heart failure population contributed $182 PMPM (17.5%), $58 PMPM (5.6%), and $46 PMPM (4.4%), respectively, to the total Medicare FFS population-allowed cost of $1045 PMPM.
Medicare FFS beneficiaries with heart failure have high inpatient admission and readmission rates and generate substantial costs. Because a substantial portion of all inpatient admissions are for Medicare beneficiaries with heart failure, it is reasonable for hospitals in Medicare accountable care organizations to focus on more aggressive post-acute care management, including a focus on reducing readmissions for the population with heart failure. Our study findings highlight areas of high service utilization and cost for Medicare patients with heart failure that can be of value to Medicare, Medicare Advantage plans, and providers.
尽管在美国,心力衰竭的医疗和经济负担已经相当沉重,但随着人口老龄化和预期寿命的增加,这一负担可能会进一步加重。不出所料,大部分心力衰竭负担由年龄≥65岁的个体承担,其中许多人参加了医疗保险。医疗保险受益人因心力衰竭住院治疗的基于人群的利用率和费用,支付方和医疗服务提供者了解得并不充分。
真实呈现医疗保险按服务收费(FFS)的心力衰竭受益人住院、再入院以及入住专业护理机构的利用率和费用情况。
本研究使用2011年和2012年医疗保险5%样本有限数据集对索赔数据进行回顾性分析。用于确定某些患者特征的回顾年份为2011年,2012年为研究分析期。心力衰竭受益人定义为在2012年有≥1次急性住院、急诊科、非急性住院或门诊索赔,且索赔中包含国际疾病分类第九版心力衰竭编码的患者。要纳入本研究,心力衰竭受益人在2012年必须有≥1个月的资格,且在2011年全年都有资格,在所有研究月份都有A部分和B部分资格,且未参加健康维护组织(医疗保险优势计划)。报告了2012年医疗保险FFS心力衰竭受益人和所有医疗保险FFS受益人的住院、再入院以及入住专业护理机构的情况。关键指标的费用包括2012年按美元计算的所有允许的医疗保险支付费用。
本研究的2012年医疗保险FFS人群包括1461935名患者(1301545名无心力衰竭;160390名有心力衰竭);心力衰竭患病率为11%。心力衰竭患者的医疗保险允许的每月人均费用(PMPM)为3395美元,而整个医疗保险人群的允许费用为1045美元PMPM。心力衰竭人群的医疗保险允许金额占医疗保险FFS人群年度总允许金额的34%。心力衰竭人群分别占医疗保险FFS住院、再入院以及入住专业护理机构总数的41.5%、55.3%和49.5%。心力衰竭人群的住院、再入院以及入住专业护理机构的费用分别为182美元PMPM(17.5%)、58美元PMPM(5.6%)和46美元PMPM(4.4%),占医疗保险FFS人群总允许费用1045美元PMPM的相应比例。
医疗保险FFS的心力衰竭受益人有较高的住院和再入院率,并产生大量费用。由于所有住院治疗中有很大一部分是针对医疗保险心力衰竭受益人,因此医疗保险责任医疗组织中的医院关注更积极的急性后护理管理是合理的,包括关注降低心力衰竭人群的再入院率。我们的研究结果突出了医疗保险心力衰竭患者高服务利用率和高费用的领域,这对医疗保险、医疗保险优势计划和医疗服务提供者可能具有价值。